losartan and Hypoxia
losartan has been researched along with Hypoxia in 33 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Hypoxia: Sub-optimal OXYGEN levels in the ambient air of living organisms.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "Obstructive sleep apnea is characterized by chronic intermittent hypoxia (CIH), which is a risk factor for renal peritubular capillary (PTC) loss, and angiotensin II receptor blockers can alleviate PTC loss." | 7.96 | Losartan protects against intermittent hypoxia-induced peritubular capillary loss by modulating the renal renin-angiotensin system and angiogenesis factors. ( Chu, Y; Jiang, Z; Wu, J; Yu, Q, 2020) |
| "Adult male Sprague Dawley rats were subjected to 8 h/day of intermittent hypoxia/normoxia, with or without losartan, a selective AT1R blocker, and/or U73122, a selective PLC inhibitor, for 8 weeks." | 7.85 | Losartan attenuates aortic endothelial apoptosis induced by chronic intermittent hypoxia partly via the phospholipase C pathway. ( Deng, Y; Jin, M; Li, GC; Liu, HG; Liu, W; Pan, YY; Ren, J; Xie, S, 2017) |
| " To test the role of the brain renin-angiotensin system (RAS) in CIH hypertension, rats were implanted with intracerebroventricular (icv) cannulae delivering losartan (1 μg/h) or vehicle (VEH) via miniosmotic pumps and telemetry devices for arterial pressure recording." | 7.79 | Central losartan attenuates increases in arterial pressure and expression of FosB/ΔFosB along the autonomic axis associated with chronic intermittent hypoxia. ( Cunningham, JT; Knight, WD; Mifflin, SW; Nedungadi, TP; Saxena, A; Shell, B, 2013) |
| " Then, lumbar sympathetic activity was recorded under anesthesia during 20-s apneas, isocapnic hypoxia, and potassium cyanide." | 7.76 | Chronic intermittent hypoxia augments chemoreflex control of sympathetic activity: role of the angiotensin II type 1 receptor. ( Bird, CE; Li, YL; Marcus, NJ; Morgan, BJ; Schultz, HD, 2010) |
| "Obstructive sleep apnea is characterized by chronic intermittent hypoxia (CIH), which is a risk factor for renal peritubular capillary (PTC) loss, and angiotensin II receptor blockers can alleviate PTC loss." | 3.96 | Losartan protects against intermittent hypoxia-induced peritubular capillary loss by modulating the renal renin-angiotensin system and angiogenesis factors. ( Chu, Y; Jiang, Z; Wu, J; Yu, Q, 2020) |
| "Adult male Sprague Dawley rats were subjected to 8 h/day of intermittent hypoxia/normoxia, with or without losartan, a selective AT1R blocker, and/or U73122, a selective PLC inhibitor, for 8 weeks." | 3.85 | Losartan attenuates aortic endothelial apoptosis induced by chronic intermittent hypoxia partly via the phospholipase C pathway. ( Deng, Y; Jin, M; Li, GC; Liu, HG; Liu, W; Pan, YY; Ren, J; Xie, S, 2017) |
| " To test the role of the brain renin-angiotensin system (RAS) in CIH hypertension, rats were implanted with intracerebroventricular (icv) cannulae delivering losartan (1 μg/h) or vehicle (VEH) via miniosmotic pumps and telemetry devices for arterial pressure recording." | 3.79 | Central losartan attenuates increases in arterial pressure and expression of FosB/ΔFosB along the autonomic axis associated with chronic intermittent hypoxia. ( Cunningham, JT; Knight, WD; Mifflin, SW; Nedungadi, TP; Saxena, A; Shell, B, 2013) |
| " Then, lumbar sympathetic activity was recorded under anesthesia during 20-s apneas, isocapnic hypoxia, and potassium cyanide." | 3.76 | Chronic intermittent hypoxia augments chemoreflex control of sympathetic activity: role of the angiotensin II type 1 receptor. ( Bird, CE; Li, YL; Marcus, NJ; Morgan, BJ; Schultz, HD, 2010) |
| "6 hamsters (DL) with losartan, an AT1 receptor blocker, affects D1 receptor density in the striatum and nucleus tractus solitarius (NTS) and normalizes ventilation during exposure to air, hypoxia, following hypoxia, and hypercapnia, Ventilation was evaluated using plethysmography." | 3.76 | In dystrophic hamsters losartan affects control of ventilation and dopamine D1 receptor density. ( Schlenker, EH, 2010) |
| "The pulmonary vasoconstriction induced by acute hypoxia was significantly attenuated during losartan infusion, while Psa, SVR, CO, pH, PaCO(2), PaO(2) and base excess did not differ between groups." | 3.74 | The role of angiotensin II receptor-1 blockade in the hypoxic pulmonary vasoconstriction response in newborn piglets. ( Bancalari, E; Camelo, JS; Camelo, SH; Devia, C; Hehre, D; Suguihara, C, 2008) |
| " Hypoxia-induced constriction of vessels from losartan-treated rats was inhibited by endothelium removal or indomethacin (1 microM)." | 3.72 | Chronic AT(1) receptor blockade alters mechanisms mediating responses to hypoxia in rat skeletal muscle resistance arteries. ( Drenjancevic-Peric, I; Frisbee, JC; Lombard, JH; Phillips, SA, 2004) |
| "Losartan could reduce pulmonary arterial collagen I expression, it may be one of the therapeutic mechanisms on hypoxic pulmonary hypertension of losartan." | 3.72 | [The effects of losartan on pulmonary arterial collagen and AT1 in chronic hypoxic rats]. ( Chen, XJ; Cheng, DY; Guan, J; Su, QL; Wang, H; Zhang, Y, 2004) |
| " Baroreflex curves were determined under conditions of normoxia and hypoxia (10% O2 + 3% CO2) before and after central administration of either Ringer solution, the ANG II receptor antagonist losartan (10 micrograms), or the angiotensin-converting enzyme inhibitor enalaprilat (500 ng) on separate days." | 3.70 | Role of central catecholaminergic pathways in the actions of endogenous ANG II on sympathetic reflexes. ( Gaudet, EA; Godwin, SJ; Head, GA, 1998) |
| " Normoxia (40 min) was followed by hypoxia (40 min, breathing 10% oxygen, arterial oxygen pressures 36 +/- 1 Torr) during both control (Con) and losartan experiments (Los; iv infusion of 100 microg." | 3.70 | Acute hypoxic pulmonary vasoconstriction in conscious dogs decreases renin and is unaffected by losartan. ( Boemke, W; Kaczmarczyk, G; Krebs, MO; Simon, S; Wenz, M, 1999) |
| "In the present study, the effects of chronic hypoxia on the expression and localization of angiotensin II (Ang II) receptors are investigated by semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) and by immunohistochemistry." | 3.70 | Chronic hypoxia upregulates the expression and function of AT(1) receptor in rat carotid body. ( Fung, ML; Lam, SY; Leung, PS, 2000) |
| "Pre-treatment with losartan, however, had no significant effect on systemic vascular resistance although losartan compared to placebo resulted in a significant (P < 0." | 2.68 | Acute hypoxic pulmonary vasoconstriction in man is attenuated by type I angiotensin II receptor blockade. ( Cargill, RI; Kiely, DG; Lipworth, BJ, 1995) |
| "Although some tumors had vessels with greater oxygen-carrying ability than those of normal skin, most tumors had inefficient vessels." | 1.72 | Multiphoton Phosphorescence Quenching Microscopy Reveals Kinetics of Tumor Oxygenation during Antiangiogenesis and Angiotensin Signaling Inhibition. ( Bawendi, MG; Brown, EB; Chauhan, VP; Duda, DG; Fukumura, D; Han, HS; Jain, RK; Kamoun, WS; Lanning, RM; Lee, H; Martin, JD; Martin, MR; Mousa, AS; Padera, TP; Stylianopoulos, T, 2022) |
| "Hypoxia produced right ventricular hypertrophy of about 100% after 3 wk, which reversed with normoxia recovery." | 1.31 | Modulation of angiotensin II receptor expression during development and regression of hypoxic pulmonary hypertension. ( Adamy, C; Adnot, S; Chassagne, C; Dubois-Randé, JL; Eddahibi, S; Marotte, F; Rideau, D; Samuel, JL; Teiger, E, 2000) |
| "These data suggest that postnatal hypoxemia is associated with an increased sensitivity of peripheral chemoreceptors in response to Ang II and an up-regulation of AT1a receptor-mediated [Ca2+]i activity of the chemoreceptors." | 1.31 | Postnatal hypoxemia increases angiotensin II sensitivity and up-regulates AT1a angiotensin receptors in rat carotid body chemoreceptors. ( Chen, Y; Dong, X; Lam, SY; Leung, PS, 2002) |
| " Meclofenamate and N omega-nitro-L-arginine methyl ester shifted the dose-response curve for ANG IV to the left in a manner similar to that observed with ANG II and ANG III." | 1.29 | Analysis of responses to ANG IV: effects of PD-123319 and DuP-753 in the pulmonary circulation of the rat. ( Feng, CJ; Kadowitz, PJ; Kaye, AD; Nossaman, BD, 1995) |
Research
Studies (33)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (27.27) | 18.2507 |
| 2000's | 10 (30.30) | 29.6817 |
| 2010's | 9 (27.27) | 24.3611 |
| 2020's | 5 (15.15) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Martin, JD | 1 |
| Lanning, RM | 1 |
| Chauhan, VP | 1 |
| Martin, MR | 1 |
| Mousa, AS | 1 |
| Kamoun, WS | 1 |
| Han, HS | 1 |
| Lee, H | 1 |
| Stylianopoulos, T | 2 |
| Bawendi, MG | 1 |
| Duda, DG | 1 |
| Brown, EB | 1 |
| Padera, TP | 1 |
| Fukumura, D | 1 |
| Jain, RK | 2 |
| Shelke, V | 1 |
| Dagar, N | 1 |
| Gaikwad, AB | 1 |
| Wu, J | 1 |
| Chu, Y | 1 |
| Jiang, Z | 1 |
| Yu, Q | 1 |
| Chiu, CZ | 1 |
| Wang, BW | 1 |
| Yu, YJ | 1 |
| Shyu, KG | 1 |
| Franzén, S | 1 |
| Näslund, E | 1 |
| Wang, H | 2 |
| Frithiof, R | 1 |
| Zhao, Y | 1 |
| Cao, J | 1 |
| Melamed, A | 1 |
| Worley, M | 1 |
| Gockley, A | 1 |
| Jones, D | 1 |
| Nia, HT | 1 |
| Zhang, Y | 2 |
| Kumar, AS | 1 |
| Mpekris, F | 1 |
| Datta, M | 1 |
| Sun, Y | 1 |
| Wu, L | 1 |
| Gao, X | 1 |
| Yeku, O | 1 |
| Del Carmen, MG | 1 |
| Spriggs, DR | 1 |
| Xu, L | 1 |
| Knight, WD | 1 |
| Saxena, A | 1 |
| Shell, B | 1 |
| Nedungadi, TP | 1 |
| Mifflin, SW | 1 |
| Cunningham, JT | 1 |
| Morgan, BJ | 3 |
| Bates, ML | 1 |
| Rio, RD | 1 |
| Wang, Z | 1 |
| Dopp, JM | 1 |
| Ren, J | 1 |
| Liu, W | 1 |
| Deng, Y | 1 |
| Li, GC | 1 |
| Pan, YY | 1 |
| Xie, S | 1 |
| Jin, M | 1 |
| Liu, HG | 1 |
| Marcus, NJ | 2 |
| Li, YL | 2 |
| Bird, CE | 2 |
| Schultz, HD | 2 |
| Schlenker, EH | 1 |
| Foster, GE | 2 |
| Hanly, PJ | 2 |
| Ahmed, SB | 2 |
| Beaudin, AE | 2 |
| Pialoux, V | 2 |
| Poulin, MJ | 2 |
| Philippi, NR | 1 |
| Drenjancevic-Peric, I | 2 |
| Lombard, JH | 2 |
| Phillips, SA | 1 |
| Frisbee, JC | 1 |
| Guan, J | 1 |
| Cheng, DY | 1 |
| Chen, XJ | 1 |
| Su, QL | 1 |
| Zoccal, DB | 1 |
| Bonagamba, LG | 1 |
| Oliveira, FR | 1 |
| Antunes-Rodrigues, J | 1 |
| Machado, BH | 1 |
| Wang, B | 1 |
| Scott, RC | 1 |
| Pattillo, CB | 1 |
| Prabhakarpandian, B | 1 |
| Sundaram, S | 1 |
| Kiani, MF | 1 |
| Camelo, JS | 1 |
| Hehre, D | 1 |
| Devia, C | 1 |
| Camelo, SH | 1 |
| Bancalari, E | 1 |
| Suguihara, C | 1 |
| Nossaman, BD | 1 |
| Feng, CJ | 1 |
| Kaye, AD | 1 |
| Kadowitz, PJ | 1 |
| Kiely, DG | 1 |
| Cargill, RI | 1 |
| Lipworth, BJ | 1 |
| Neylon, M | 1 |
| Marshall, J | 1 |
| Johns, EJ | 1 |
| Morrell, NW | 1 |
| Bendle, RD | 1 |
| Malpas, SC | 1 |
| Head, GA | 2 |
| Gaudet, EA | 1 |
| Godwin, SJ | 1 |
| Krebs, MO | 1 |
| Boemke, W | 1 |
| Simon, S | 1 |
| Wenz, M | 1 |
| Kaczmarczyk, G | 1 |
| Fletcher, EC | 1 |
| Bao, G | 1 |
| Li, R | 1 |
| Pape, D | 1 |
| Goineau, S | 1 |
| Guillo, P | 1 |
| Durand-Castel, X | 1 |
| Bellissant, E | 1 |
| Chassagne, C | 1 |
| Eddahibi, S | 1 |
| Adamy, C | 1 |
| Rideau, D | 1 |
| Marotte, F | 1 |
| Dubois-Randé, JL | 1 |
| Adnot, S | 1 |
| Samuel, JL | 1 |
| Teiger, E | 1 |
| Leung, PS | 2 |
| Lam, SY | 2 |
| Fung, ML | 1 |
| Lonchampt, M | 1 |
| Pennel, L | 1 |
| Duhault, J | 1 |
| Dong, X | 1 |
| Chen, Y | 1 |
Trials
3 trials available for losartan and Hypoxia
| Article | Year |
|---|---|
Intermittent hypoxia increases arterial blood pressure in humans through a Renin-Angiotensin system-dependent mechanism.
Topics: Adult; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cerebrovascula | 2010 |
Losartan abolishes oxidative stress induced by intermittent hypoxia in humans.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Angiotensin II Type 1 Receptor Blockers; Cross-Over Studies; Deoxyguano | 2011 |
Acute hypoxic pulmonary vasoconstriction in man is attenuated by type I angiotensin II receptor blockade.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Heart R | 1995 |
Other Studies
30 other studies available for losartan and Hypoxia
| Article | Year |
|---|---|
Multiphoton Phosphorescence Quenching Microscopy Reveals Kinetics of Tumor Oxygenation during Antiangiogenesis and Angiotensin Signaling Inhibition.
Topics: Angiotensins; Animals; Hypoxia; Losartan; Mice; Microscopy; Neoplasms; Oxygen; Receptors, Angiotensi | 2022 |
Phloretin as an add-on therapy to losartan attenuates diabetes-induced AKI in rats: A potential therapeutic approach targeting TLR4-induced inflammation.
Topics: Acute Kidney Injury; Animals; Diabetes Mellitus, Experimental; Hypoxia; Inflammation; Kidney; Losart | 2023 |
Losartan protects against intermittent hypoxia-induced peritubular capillary loss by modulating the renal renin-angiotensin system and angiogenesis factors.
Topics: Angiogenesis Inducing Agents; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Body | 2020 |
Hyperbaric oxygen activates visfatin expression and angiogenesis via angiotensin II and JNK pathway in hypoxic human coronary artery endothelial cells.
Topics: Angiotensin II; Anthracenes; Cell Movement; Cells, Cultured; Coronary Vessels; Cytokines; Endothelia | 2020 |
Prevention of hemorrhage-induced renal vasoconstriction and hypoxia by angiotensin II type 1 receptor antagonism in pigs.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Hemodynamics; Hemorrhage; | 2021 |
Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma.
Topics: Animals; Antineoplastic Agents; Ascites; Collagen; Disease Models, Animal; Drug Synergism; Extracell | 2019 |
Central losartan attenuates increases in arterial pressure and expression of FosB/ΔFosB along the autonomic axis associated with chronic intermittent hypoxia.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arterial Pressure; Autonomic Nervous System; Brain | 2013 |
Oxidative stress augments chemoreflex sensitivity in rats exposed to chronic intermittent hypoxia.
Topics: Acetophenones; Allopurinol; Analysis of Variance; Animals; Anti-Arrhythmia Agents; Antioxidants; Bod | 2016 |
Losartan attenuates aortic endothelial apoptosis induced by chronic intermittent hypoxia partly via the phospholipase C pathway.
Topics: Animals; Aorta; Apoptosis; Endothelial Cells; Hypoxia; Losartan; Male; Rats; Rats, Sprague-Dawley; T | 2017 |
Chronic intermittent hypoxia augments chemoreflex control of sympathetic activity: role of the angiotensin II type 1 receptor.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Apnea; Blood Pressure; Carotid Bod | 2010 |
In dystrophic hamsters losartan affects control of ventilation and dopamine D1 receptor density.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Body Weight; Corpus Striatum; Cricetinae; Disease | 2010 |
Effect of AT1 receptor blockade on intermittent hypoxia-induced endothelial dysfunction.
Topics: Acetylcholine; Angiotensin II Type 1 Receptor Blockers; Animals; Arteries; Endothelium, Vascular; Hy | 2012 |
Introgression of chromosome 13 in Dahl salt-sensitive genetic background restores cerebral vascular relaxation.
Topics: Acetylcholine; Angiotensin II Type 1 Receptor Blockers; Animals; Cerebral Arteries; Chromosomes; Die | 2004 |
Chronic AT(1) receptor blockade alters mechanisms mediating responses to hypoxia in rat skeletal muscle resistance arteries.
Topics: Acetylcholine; Angiotensin II Type 1 Receptor Blockers; Animals; Arteries; Cardiovascular Agents; En | 2004 |
[The effects of losartan on pulmonary arterial collagen and AT1 in chronic hypoxic rats].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Chronic Disease; Collagen; Hypertension, Pulmonary | 2004 |
Increased sympathetic activity in rats submitted to chronic intermittent hypoxia.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Chronic Disease; Disease Models, A | 2007 |
Microvascular transport model predicts oxygenation changes in the infarcted heart after treatment.
Topics: Angiogenesis Inducing Agents; Angiotensin II Type 1 Receptor Blockers; Animals; Computer Simulation; | 2007 |
The role of angiotensin II receptor-1 blockade in the hypoxic pulmonary vasoconstriction response in newborn piglets.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Animals; Animals, Newborn | 2008 |
Analysis of responses to ANG IV: effects of PD-123319 and DuP-753 in the pulmonary circulation of the rat.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1995 |
The role of the renin-angiotensin system in the renal response to moderate hypoxia in the rat.
Topics: Animals; Biphenyl Compounds; Blood Pressure; Hypoxia; Imidazoles; Kidney; Losartan; Rats; Rats, Wist | 1996 |
Use of pulsed-wave Doppler echocardiography to measure changes in MPAP. Is further validation required?
Topics: Acute Disease; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhib | 1997 |
Role of endogenous angiotensin II on sympathetic reflexes in conscious rabbits.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Baroreflex; Biphenyl Compounds; Blood Pressure; Ca | 1997 |
Role of central catecholaminergic pathways in the actions of endogenous ANG II on sympathetic reflexes.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1998 |
Acute hypoxic pulmonary vasoconstriction in conscious dogs decreases renin and is unaffected by losartan.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Bicarbonates; Blood Gas Analysis; Blood Pressure; | 1999 |
Renin activity and blood pressure in response to chronic episodic hypoxia.
Topics: Adrenal Medulla; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Chem | 1999 |
Endothelin, but not angiotensin II, contributes to the hypoxic contractile response of large isolated pulmonary arteries in the rat.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhib | 1999 |
Modulation of angiotensin II receptor expression during development and regression of hypoxic pulmonary hypertension.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Antihypertensive Agents | 2000 |
Chronic hypoxia upregulates the expression and function of AT(1) receptor in rat carotid body.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Carotid Body; Chemoreceptor Cells; Chroni | 2000 |
Hyperoxia/normoxia-driven retinal angiogenesis in mice: a role for angiotensin II.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 2001 |
Postnatal hypoxemia increases angiotensin II sensitivity and up-regulates AT1a angiotensin receptors in rat carotid body chemoreceptors.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Animals, Newborn; Calcium; Carotid Body; | 2002 |